US Patent

US11224661 — Controlled-release CNP agonists with increased NEP stability

Composition of Matter · Assigned to Ascendis Pharma Growth Disorders AS · Expires 2037-01-05 · 11y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects controlled-release CNP agonists with increased NEP stability and their use in pharmaceutical compositions for treatment methods.

USPTO Abstract

The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.

Drugs covered by this patent

Patent Metadata

Patent number: US11224661
Jurisdiction: US
Classification: Composition of Matter
Expires: 2037-01-05
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Ascendis Pharma Growth Disorders AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.